Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $110.00

Vera Therapeutics (NASDAQ:VERA) had its price target increased by HC Wainwright from $90.00 to $110.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently issued reports on VERA. Evercore boosted their price target on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 8th. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. JPMorgan Chase & Co. reduced their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. Finally, Pivotal Research set a $73.00 price target on Vera Therapeutics in a research note on Friday, December 5th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $80.80.

Vera Therapeutics Trading Up 0.9%

Shares of VERA opened at $39.65 on Monday. The stock has a market capitalization of $2.78 billion, a P/E ratio of -8.51 and a beta of 1.17. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12. The firm has a fifty day simple moving average of $45.45 and a two-hundred day simple moving average of $35.98. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter in the previous year, the firm posted ($0.72) EPS. On average, research analysts anticipate that Vera Therapeutics will post -2.89 EPS for the current year.

Insiders Place Their Bets

In other Vera Therapeutics news, COO David Lee Johnson sold 2,579 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $108,266.42. Following the completion of the transaction, the chief operating officer owned 45,727 shares of the company’s stock, valued at approximately $1,919,619.46. This trade represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Joseph R. Young sold 3,117 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $130,851.66. Following the sale, the senior vice president owned 64,722 shares in the company, valued at approximately $2,717,029.56. This trade represents a 4.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 33,490 shares of company stock valued at $1,405,910 in the last 90 days. Corporate insiders own 16.30% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Vera Therapeutics by 7.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after purchasing an additional 2,210 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Vera Therapeutics by 22.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after buying an additional 17,907 shares during the last quarter. Jane Street Group LLC boosted its holdings in Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after acquiring an additional 62,678 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Vera Therapeutics in the second quarter worth $237,000. Finally, Quinn Opportunity Partners LLC purchased a new stake in shares of Vera Therapeutics in the second quarter worth $448,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.